2. Academic Validation
  3. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis

Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis

  • Maturitas. 2017 Mar:97:53-60. doi: 10.1016/j.maturitas.2016.12.003.
Chee Kian Chew 1,  Bart L Clarke 2
Affiliations

Affiliations

  • 1 Mayo Clinic E18-A, 200 1st Street SW, Rochester, MN, 55905 USA.
  • 2 Mayo Clinic E18-A, 200 1st Street SW, Rochester, MN, 55905 USA. Electronic address: [email protected].
PMID: 28159062 DOI: 10.1016/j.maturitas.2016.12.003
Abstract

The treatment of osteoporosis is generally either by inhibition of bone resorption with antiresorptive agents or by stimulation of bone formation with anabolic agents. Currently, teriparatide (recombinant human parathyroid hormone 1-34 [rhPTH (1-34)]) is the only available approved anabolic agent in the U.S. Other anabolic agents are under investigation however. Abaloparatide is recombinant human parathyroid hormone-related peptide 1-34. This agent is an anabolic agent that appears more potent than teriparatide, and it may have more rapid onset of fracture reduction than teriparatide. It is currently undergoing FDA review, with approval expected in 2017.

Keywords

Abaloparatide; Anabolic agents; Fractures; Osteoporosis; PTHrP 1–34.

Figures
Products